Ocuphire Pharma Investor Presentation Deck
ZETA-1: Baseline Demographics and Systemic Characteristics
Well-Balanced Across Arms
Demographics
Age (years)
mean
(range)
Sex: Male n (%)
Race: White n (%)
Ethnicity: Hispanic or
Latino n (%)
Diabetes Status (years)
mean
(range)
Systolic Blood Pressure
(mmHg)
mean
Diastolic Blood Pressure
(mmHg)
mean
Heart Rate (beats/min)
mean
Hemoglobin A1C (%)
mean
Body Mass Index
(kg/m^2)
mean
Ocuphire
APX3330
n=51
54.3
(26-81)
24 (47%)
40 (78%)
28 (55%)
15
(0-36)
136
82
77
8.4
31
Placebo
n=52
ZETA-1 Clinical Trial
58.3
(24-78)
26 (50%)
41 (79%)
23 (44%)
16
(0-58)
139
80
76
8.3
31
DRSS Scores
APX3330
n=49
DRSS Score - Study Eye
47 (Moderately severe to severe
NPDR)
53 (Moderately severe to severe
NPDR)
61 (Mild proliferative diabetic
retinopathy)
DRSS Score - Fellow Eye
43 or Lower (Mild to moderate
NDPR or better)
47 (Moderately severe to severe
NPDR)
53 (Moderately severe to severe
NPDR)
61 (Mild proliferative diabetic
retinopathy)
65 or Higher (Moderate to
severe prolif. DR)
22 (43%)
25 (49%)
4 (8%)
15 (31%)
15 (31%)
12 (25%)
1 (2%)
6 (12%)
Placebo
n=52
18 (35%)
28 (54%)
6 (12%)
13 (25%)
20 (38%)
10 (19%)
4 (8%)
5 (10%)
Note: 15 fellow eyes were CST>320 microns
(center-involved DME eyes)
Key Visual Metrics
APX3330
n=51
Placebo
n=52
BCVA Study
Eye
Letters (mean)
BCVA Fellow
Eye
Letters (mean)
OCT CST
Study Eye
(μm)
OCT
CST Fellow
Eye (um)
Intraretinal
Fluid in the
Center of SE
Intraretinal
Fluid at the
Foveal Cente
r of SE
Intraocular
Pressure in
Study Eye
(mmHg)
81
76
270
292
Y - 21
N - 26
Y-1
N - 20
15
78
77
271
286
Y - 12
N - 31
Y-1
N-11
16
Total
n=103
80
(20/25
Snellen)
77
(20/32
Snellen)
271
289
Y - 33
N - 57
Y-2
N - 31
15
21
Good Visual Acuity Fluid Below 320μmView entire presentation